Cancer Immunology, Immunotherapy

, Volume 64, Issue 7, pp 923–930

Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6–8, 2014

  • Björn-Philipp Kloke
  • Andrea Mahr
  • Robert A. Jabulowsky
  • Sarah Kutscher
  • Richard Rae
  • Cedrik M. Britten
Meeting Report

DOI: 10.1007/s00262-014-1643-7

Cite this article as:
Kloke, BP., Mahr, A., Jabulowsky, R.A. et al. Cancer Immunol Immunother (2015) 64: 923. doi:10.1007/s00262-014-1643-7

Keywords

CIMT 2014 Cancer immunotherapy Cancer immunology Tumor vaccination 

Abbreviations

Ab

Antibody

ACT

Adoptive cellular transfer

ADCC

Antibody-dependent cellular cytotoxicity

ATG

Anti-thymocyte globulin

BTN3A1

Butyrophilin 3A1

CAR

Chimeric antigen receptor

CIMT

Association for Cancer Immunotherapy

CIP

CIMT Immunoguiding Program

CT

Cancer–testis

CTLA-4

Cytotoxic T-lymphocyte-associated protein 4

CTL

Cytotoxic T lymphocytes

CTX

Cyclophosphamide

DNAM-1

DNAX Accessory Molecule-1

FasL

Fas ligand

IFA

Incomplete Freud’s adjuvant

IL-10

Interleukin 10

LP

Long peptides

PD-1

Programmed cell death 1

PD-L1

Programmed death-ligand 1

PGE2

Prostaglandin E2

RRG

CIMT Regulatory Research group

SP

Short peptides

Teff

T effector cells

TERS

TCR-engineered reference samples

TIGIT

T cell immunoreceptor with Ig and ITIM domains

Treg

T regulatory cells

VEGF-A

Vascular endothelial growth factor A

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Björn-Philipp Kloke
    • 1
  • Andrea Mahr
    • 2
  • Robert A. Jabulowsky
    • 1
  • Sarah Kutscher
    • 2
  • Richard Rae
    • 3
  • Cedrik M. Britten
    • 1
    • 3
  1. 1.BioNTech RNA Pharmaceuticals GmbHMainzGermany
  2. 2.Immatics Biotechnologies GmbHTübingenGermany
  3. 3.TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg UniversityMainzGermany

Personalised recommendations